The Effects of RT-CGM on Glycemia and QoL in Patients With T1DM and IHA

Inclusion Criteria: * T1DM, diagnosed according to ADA criteria regardless duration * Use of multiple daily injections of insulin (with a basal insulin injection and bolus injections) or continuous subcutaneous insulin infusion * Any HbA1c * Age between 18 and 70 years old (inclusive) * IHA according to the questionnaire by Gold et al. * Performing at least 3 SMBG/day or 21 SMBG/week Exclusion Criteria: * Type 2 diabetes mellitus * History of (recent) major renal, liver, or (ischemic) heart disease (including cardiac conduction disorders) * Current untreated proliferative diabetic retinopathy * Current (treatment for) malignancy * Current use of non-selective beta-blockers * Current psychiatric disorders, including schizophrenia, bipolar disorder, anorexia nervosa or bulimia nervosa * Substance abuse or alcohol abuse (men \>21 units/week, women \>14 units/week) * Current pregnancy or intention to conceive * Current use of RT-CGM other than for short term (i.e. diagnostic use or use shorter than 3 consecutive months) * Hearing or vision impairment hindering perceiving of glucose display and alarms, or otherwise incapable of using a (RT-)CGM, in the opinion of the investigator * Poor commandment of the Dutch language or any (mental) disorder that precludes full understanding of the purpose and instructions of the study * Participation in another clinical study * Known or suspected allergy to trial product or related products